PYOTT DAVID E I 4

What Happened

• David E. Pyott, a director of Tarsus Pharmaceuticals, received two equity awards on February 18, 2026: 5,893 option shares (derivative) and 3,729 restricted stock units (RSUs). Both items are recorded at $0.00 in the Form 4 (no cash paid on grant) and are awards rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely).
• Awards: 5,893 option shares (derivative) and 3,729 RSUs — total 9,622 units.
• Price shown in filing: $0.00 (awarded, not purchased).
• Vesting — options (F1): vest in three equal annual installments on Feb 18 of 2027, 2028, and 2029, subject to continuous service. RSUs (F2/F3): each RSU represents one share and vests in three equal annual installments on March 15 of 2027, 2028, and 2029, subject to continuous service.
• Shares owned after the reported transactions: not specified in the provided summary of the filing.
• No immediate sale, tax‑withholding sale, or 10b5-1 plan indicated in the reported items.

Context

• These are compensation awards (one option grant and one RSU grant) that vest over time and do not reflect an immediate cash transaction or open‑market buying/selling. Such grants are common as director compensation; they increase potential future ownership if vesting conditions are met but do not represent an immediate investment by the insider.